financetom
Business
financetom
/
Business
/
Nippon Steel to make additional investment in US Steel's mills
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nippon Steel to make additional investment in US Steel's mills
Aug 31, 2024 5:12 AM

TOKYO (Reuters) - Japan's biggest steelmaker Nippon Steel said on Thursday it plans to make an additional investment of about $1.3 billion in U.S. Steel's two mills as part of its pending acquisition of the U.S. company.

The spending is on top of the $1.4 billion investment plan through 2026 already pledged as part of the takeover proposal, a company spokesperson said, adding some of the expenditures are expected to occur beyond 2027.

The fresh spending plan includes at least $1 billion to increase the capacity for high-grade steel at Mon Valley Works in Pennsylvania and $0.3 billion to upgrade facilities to extend its production life at Gary Works in Indiana, Nippon Steel said.

Nippon Steel, which clinched the $14.9 billion deal to buy U.S. Steel last December, has committed to spending at least $1.4 billion on maintenance and other capital investments in U.S. Steel's existing facilities, though details have not been disclosed.

Both steelmakers have received all regulatory approvals outside of the United States for the deal, but face political opposition, U.S. regulatory scrutiny and objections from the powerful United Steelworkers (USW) union, which fears the deal could lead to job losses.

The investments are subject to the closing of the transaction and receipt of any necessary regulatory approvals, Nippon Steel said, adding detailed design and specification will be determined through further engineering studies.

The world's fourth-biggest steelmaker expects the acquisition deal to close in the second half of 2024.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US CFPB data security 'not effective' after Trump clampdown, watchdog report says
US CFPB data security 'not effective' after Trump clampdown, watchdog report says
Nov 3, 2025
WASHINGTON (Reuters) -President Donald Trump's clampdown on the U.S. Consumer Financial Protection Bureau earlier this year has compounded IT security lapses at the agency through the cancellation of contracts, according to an audit report released on Monday. The information security program at CFPB -- which maintains sensitive and confidential data from investigations, the oversight of companies and complaints received from...
Cantor Equity Partners V, Inc. Announces Pricing of Upsized $220 Million Initial Public Offering
Cantor Equity Partners V, Inc. Announces Pricing of Upsized $220 Million Initial Public Offering
Nov 3, 2025
NEW YORK--(BUSINESS WIRE)-- Cantor Equity Partners V, Inc. (the “Company”) announced today the pricing of its upsized initial public offering of 22,000,000 Class A ordinary shares at $10.00 per share. The shares are expected to be listed on the Nasdaq Global Market under the symbol “CEPV” and begin trading on November 4, 2025. The underwriters have been granted a 45-day...
Pfizer accuses Novo Nordisk of anticompetitive plot to stall Metsera deal in lawsuit
Pfizer accuses Novo Nordisk of anticompetitive plot to stall Metsera deal in lawsuit
Nov 3, 2025
* Lawsuit alleges Novo's 30-month closing period would stall Metsera's ( MTSR ) obesity drug * Metsera ( MTSR ) says Pfizer ( PFE ) using litigation to lower its takeover price * Judge will analyze claims on Tuesday By Sabrina Valle, Mrinalika Roy and Tom Hals Nov 3 (Reuters) - Pfizer ( PFE ) filed a second lawsuit on...
Pfizer accuses Novo Nordisk of anticompetitive plot to stall Metsera deal in lawsuit
Pfizer accuses Novo Nordisk of anticompetitive plot to stall Metsera deal in lawsuit
Nov 3, 2025
(Reuters) -Pfizer filed a second lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for biotech Metsera to stall, not close, the deal, a tactic it said is designed to suppress competition in obesity drugs.  Novo and Metsera on Monday rejected Pfizer's claims, in a dramatic escalation in the legal and bidding fight for control...
Copyright 2023-2026 - www.financetom.com All Rights Reserved